Opioid Use Disorder: Clinical Trials

160 completed, 129 recruiting, 42 active not recruiting, 40 not yet recruiting. 231 Not applicable, 53 Phase 2, 48 Phase 1, 33 Phase 4, 21 Phase 3.

By phase and status

Phase	Trials	Status
Not applicable	231	Completed 88, Recruiting 64, Active not recruiting 27, Not yet recruiting 20, Unknown 10, Enrolling by invitation 8, Terminated 7, Withdrawn 5, Suspended 2
Phase 2	53	Recruiting 22, Completed 13, Withdrawn 7, Not yet recruiting 6, Active not recruiting 2, Unknown 2, Terminated 1
Phase 1	48	Completed 25, Recruiting 9, Active not recruiting 5, Terminated 3, Not yet recruiting 2, Unknown 2, Withdrawn 2
Phase 4	33	Recruiting 11, Completed 8, Not yet recruiting 5, Active not recruiting 3, Withdrawn 3, Terminated 2, Enrolling by invitation 1
Phase 3	21	Completed 8, Recruiting 6, Active not recruiting 3, Not yet recruiting 2, Terminated 1, Withdrawn 1
Early Phase 1	14	Completed 6, Recruiting 4, Not yet recruiting 2, Terminated 1, Withdrawn 1

Follow Opioid Use Disorder: new trials by email Literature Review of Opioid Use Disorder trials Research Report on Opioid Use Disorder

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Dynamic Treatment Regimes for Opioid Use Disorder Medication for opioid use disorder, psychotherapy - Opioid Use Disorder	Phase 2	Not yet recruiting	Brigham and Women's Hospital	75	2028-07-01	2025-11-04
Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans Integrated care - Opioid Use Disorder, HIV	Not applicable	Not yet recruiting	VA Office of Research and Development	60	2028-04-03	2026-04-24
Family-Focused Study to Support Medication for Opioid Use Disorder FamilyCHESS, Standard of Care - Opioid Use Disorder, Opioid Use Disorder, Moderate	Not applicable	Not yet recruiting	University of Wisconsin, Madison	338	2027-08-31	2026-07-07
Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, Matching Oral Placebo - Opioid Use Disorder, Opioid Withdrawal	Phase 1 / Phase 2	Not yet recruiting	Clive Michelsen	60	2027-07-01	2026-10-13
Real-World Evaluation of Compl-AI for Predicting Early Medication Dropout in Opioid Use Disorder Treatment Opioid Use Disorder		Not yet recruiting	Tools4Patient	295	2027-06-01	2026-10-01
TMS to Improve Recovery Outcomes Among Patients With Opioid Use Disorder (OUD) and Alcohol Use Disorder (AUD) TMS Low-Dose, TMS High-Dose - Alcohol Use Disorder, Opioid Use Disorder	Not applicable	Recruiting	Washington State University	60	2027-06-01	2026-05-29
Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder Psilocybin - Opioid Use Disorder	Phase 2	Withdrawn	Johns Hopkins University		2027-04-01	2026-02-23
Examining Analgesic Synergy and Efficacy in Trauma Care Buprenorphine, Oxycodone - Opioid Use Disorder	Phase 4	Not yet recruiting	Wake Forest University Health Sciences	282	2027-03-01	2026-10-28
The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study Community Paramedic Standard of Care (CP SOC), CROSSROADS - Opioid Use Disorder, Overdose, Drug	Not applicable	Not yet recruiting	Duke University	400	2027-02-01	2026-10-14
Clinician Practice Companion to Address Youth Substance Use Practice Companion - Substance Use, Substance-Related Disorders	Not applicable	Not yet recruiting	Massachusetts General Hospital	60	2027-01-01	2026-10-07
Deep Transcranial Magnetic Stimulation for Tobacco Cessation in Adults With Opioid Use Disorder Deep TMS System With H4 Coil - Opioid Use Disorder, Tobacco Use Disorder	Not applicable	Not yet recruiting	Payel Roy	12	2027-01-01	2026-08-27
Evaluation of the O'Neil Long Acting Naltrexone Implant in Opioid Dependent Persons naltrexone implant - Opioid Use Disorder	Phase 2	Not yet recruiting	Go Medical Industries Pty Ltd	250	2027-01-01	2026-09-28
Peer-led, Mobile App Supported Linkage to Opioid Use Disorder Treatment Mobile phone-assisted intervention, Peer navigator, Standard of care referral for out-patient MAT - Opioid Use Disorder	Not applicable	Not yet recruiting	Johns Hopkins University	90	2027-01-01	2026-10-28
Disease Intervention Specialist (DIS) for SUD Substance Use Disorder (SUD), Opioid Use Disorder		Not yet recruiting	Ohio State University	1200	2026-12-01	2026-10-15
Measurement-Based Care to Support Buprenorphine-Naloxone Treatment in Outpatient Addiction Clinics Bup-MBC - Opioid Use Disorder	Not applicable	Not yet recruiting	Vanderbilt University Medical Center	140	2026-12-01	2026-09-30
Evaluating a Digital Toolkit for IPV Digital Toolkit - Opioid Use Disorder	Not applicable	Not yet recruiting	Medical University of South Carolina	792	2026-12-01	2026-05-20
Cannabis Effects on Opioid Self-Administration Cannabis, Placebo Cannabis, Intranasal Opioid Agonist - Opioid Use Disorder, Cannabis Use	Phase 1	Not yet recruiting	Shanna Babalonis, PhD	30	2026-11-30	2026-10-14
Real World Evaluation of the Effectiveness and Implementation of a Digital Health Therapeutic for OUD KIOS App - Opioid Use Disorder	Not applicable	Not yet recruiting	The University of Texas Health Science Center at San Antonio	134	2026-11-30	2026-10-27
Digital Treatment for Chronic Pain and Addiction in Veterans With Opioid Use Disorder Receiving Buprenorphine Integrating the Management of Pain and Addiction via Collaborative Treatment (IMPACT), Enhanced Treatment as Usual (ETAU) - Opioid Use Disorder, Chronic Pain	Phase 3	Not yet recruiting	VA Office of Research and Development	250	2026-11-02	2026-09-17
Measuring the Effects of Neurostimulation on Risky and Ambiguous Decision-Making Capacity in People With and Without Substance Use Disorder TMS (MagVenture MagPro 100 with MagOption) - Opioid Use Disorder, Healthy Volunteers	Not applicable	Suspended	National Institute on Drug Abuse (NIDA)	2	2026-11-02	2026-10-28

Showing 20 of 439. Sign in to see all of them.

Narrower conditions

Opioid-Related Disorders (439)  ·  Substance-Related Disorders (57)  ·  Chronic Pain (34)  ·  Behavior, Addictive (17)  ·  Pain (16)  ·  Alcoholism (14)  ·  Stress Disorders, Post-Traumatic (12)  ·  Harm Reduction (10)  ·  Opiate Overdose (9)  ·  Anxiety Disorders (8)  ·  Drug Overdose (8)  ·  Depression (7)  ·  Emergencies (7)  ·  Hepatitis C (7)  ·  Pain, Postoperative (7)

Broader conditions

Chemically-Induced Disorders (435)  ·  Mental Disorders (434)  ·  Narcotic-Related Disorders (434)  ·  Substance-Related Disorders (382)  ·  Pathological Conditions, Signs and Symptoms (71)  ·  Behavior (69)  ·  Signs and Symptoms (54)  ·  Neurologic Manifestations (53)  ·  Pain (34)  ·  Pathologic Processes (25)  ·  Infections (18)  ·  Compulsive Behavior (17)  ·  Drug Misuse (17)  ·  Impulsive Behavior (17)  ·  Prescription Drug Misuse (17)

Interventions

Buprenorphine (32)  ·  Buprenorphine, Naloxone Drug Combination (25)  ·  Therapeutics (16)  ·  Sublocade (10)  ·  Cannabidiol (8)  ·  Methadone (8)  ·  Psilocybin (8)  ·  Hydromorphone (7)  ·  Naloxone (7)  ·  Dosage Forms (6)  ·  Naltrexone (6)  ·  Blood Specimen Collection (5)  ·  Morphine (5)  ·  Oxycodone (5)  ·  Telemedicine (5)

Sponsors

Yale University (32)  ·  University of Pennsylvania (14)  ·  Indivior Inc. (12)  ·  University of Maryland, Baltimore (12)  ·  Friends Research Institute, Inc. (10)  ·  Johns Hopkins University (10)  ·  Brigham and Women's Hospital (8)  ·  Medical University of South Carolina (8)  ·  NYU Langone Health (7)  ·  VA Office of Research and Development (7)  ·  Boston Medical Center (6)  ·  Duke University (6)  ·  New York State Psychiatric Institute (6)  ·  University of Wisconsin, Madison (6)  ·  Indiana University (5)

Countries

United States (397)  ·  Canada (15)  ·  Sweden (4)  ·  Turkey (Türkiye) (3)  ·  Australia (2)  ·  France (2)  ·  Taiwan (2)  ·  Ukraine (2)  ·  United Kingdom (2)  ·  Denmark (1)  ·  Egypt (1)  ·  Germany (1)  ·  Hungary (1)  ·  Kazakhstan (1)  ·  Kyrgyzstan (1)

Top investigators

Edward Melnick, MD, MHS (3)  ·  Frederick G Moeller, MD (3)  ·  Gail D'Onofrio, MD, MS (3)  ·  Yasmin Hurd, PhD (3)  ·  Adam Bisaga, MD (2)  ·  Alene Kennedy-Hendricks, PhD (2)  ·  Amber M Jarnecke, PhD (2)  ·  Anahita Bassir Nia, MD (2)  ·  Cecilia L Bergeria, PhD (2)  ·  David Farabee, PhD (2)  ·  Elise Marino, PhD (2)  ·  Frederick L Altice, MD (2)  ·  James E Swain, MD, PhD (2)

Results publications

PMID 35287034, PMID 34752714, PMID 37657559, PMID 40342086, PMID 10870744, PMID 11165371, PMID 11786502, PMID 14621285, PMID 14756584, PMID 15647484, PMID 15734224, PMID 15800228, PMID 16508405, PMID 17123731, PMID 17237664, PMID 17433624, PMID 17635557, PMID 17853395, PMID 18294378, PMID 18362258, PMID 18378801, PMID 18419722, PMID 18619874, PMID 18774343, PMID 19172249, PMID 19409861, PMID 19789074, PMID 20031953, PMID 20086062, PMID 21029787, PMID 21148579, PMID 21249671, PMID 21412914, PMID 21549528, PMID 21745048, PMID 21765969, PMID 22336864, PMID 22494121, PMID 22898544, PMID 24661411, PMID 24867013, PMID 25221944, PMID 25418676, PMID 25563446, PMID 25784600, PMID 25872113, PMID 25957198, PMID 26029937, PMID 26650971, PMID 26987082

NIH funding

R33DA059884 (4), 1RM1DA055310-01 (2), 2025 (2), 3UG1DA015831-24S1 (2), K12DA031794 (2), K23DA055695 (2), R01DA047368 (2), R61DA057610 (2), R61DA057675 (2), RM1DA055301 (2), RM1DA055311 (2), U54DA037842 (2), UG1DA013732 (2), UG3DA051392 (2), 1IK2CX002822-01A1 (1)